1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1620
  5. Art Unit 1628
  6. Examiner Rodriguez

Examiner Rodriguez Rayna B

1628-RODRIGUEZ-RAYNA-B

Employment Information

Art Unit:1628 — Drug, bio-affecting and body treating compositions
Group:1620 — Biomedicinal Chemistry
Classes: 514 — Drug, bio-affecting and body treating compositions
424 — Drug, bio-affecting and body treating compositions
544 — Organic compounds -- part of the class 532-570 series
562 — Organic compounds -- part of the class 532-570 series
548 — Organic compounds -- part of the class 532-570 series
540 — Organic compounds -- part of the class 532-570 series
604 — Surgery
546 — Organic compounds -- part of the class 532-570 series
600 — Surgery
435 — Chemistry: molecular biology and microbiology
Phone:(571) 272-7088
Email:rayna.rodriguez@uspto.gov
Location:VA 22314
Title:Pat Examnr (Biolgy)
Service:14 years
Grade:GS-14

Grant Rate and Difficulty Ranking

92
3-Year Grant rate: 25% over 322 cases
Difficulty: Extremely Hard
Difficulty Percentile: 92nd

With Examiner Rodriguez, you have a 25% chance of getting an issued patent by 3 years after the first office action. Examiner Rodriguez is an extremely hard examiner and in the 92nd percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Rodriguez, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1628

Examiner Rodriguez's grant rate is lower than that of Art Unit 1628 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Rodriguez 1.8
Art Unit 1628 1.7

Interview Benefit

Grant Rate without Interview

Examiner Rodriguez has granted 57 of 230 cases without any applicant-requested interviews for a grant rate of 25%.

Grant Rate with Interview

Examiner Rodriguez has granted 25 of 92 cases with at least one applicant-requested interview for a grant rate of 27%.

Interview Benefit

With Examiner Rodriguez, conducting an interview increases your chance of getting a patent granted by 8%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
18028145 Alpha-2 Adrenergic Receptor Antagonist Rejection information available with a Premium Stats subscription. See our pricing. Abandoned View
18043077 Methods Of Treating Age-Related Cognitive Decline Abandoned View
18042785 Methods Of Treating Age-Related Cognitive Decline Abandoned View
18041415 Analgesic Agent Abandoned View
18021189 Alcohol-Based Disinfectant Foam Abandoned View
18000504 Use Of A Combination Of Colchicine And A Cxcr-2 Inhibitors For The Treatment Or Prevention Of Familial Mediterranean Fever (Fmf) And Flare-Ups Thereof Abandoned View
17415065 Treatment Of Gastrointestinal Disorders And Symptoms Thereof Abandoned View
18231957 Fragrances With Note Of Lily Of The Valley Patented View
18021916 Pharmaceutical Composition For Prevention Or Treatment Of Degenerative Brain Diseases Comprising Abemaciclib As Active Ingredient Abandoned View
17982182 Heterodimers Of Glutamic Acid Patented View
17997978 Method To Treat Viral Infection Induced By A Coronavirus Abandoned View
17982846 Methods Of Treating Or Preventing Viral Infection With Fluorinated Alphav Integrin Antagonists Abandoned View
18390829 Eye Drops To Treat Chemically Induced Corneal Damage Patented View
18001539 Synthesis Of (2s,5r)-5-(2-Chlorophenyl)-1-(2'-Methoxy-[1,1'-Biphenyl]-4- Carbonyl)pyrrolidine-2-Carboxylic Acid Patented View
17682205 Method For Treating Hyperhidrosis Abandoned View
15939831 Uses Of (+)-B-Dihydrotetrabenazine In Methods Of Treating Movement Disorder Patented View
17916855 Methods, Compositions And Devices For Treating Mild Traumatic Brain Injury, Post Traumatic Stress Disorder And Mild Traumatic Brain Injury With Post Traumatic Stress Disorder Abandoned View
17995143 Isoquinoline Derivatives For Use In Therapy Abandoned View
17428976 Combination Therapy For Treatment Of Brain Disorders Abandoned View
18021282 Compound, Aldehyde Dehydrogenase 2 Activating Agent, Pharmaceutical Composition, And Therapeutic And/or Prophylactic Drug Patented View
15765124 Methods Of Cancer Treatment Patented View
17996892 Novel Compound [2-(Dimethylamino)-2-Phenylbutyl]-3,4,5-Trimethoxybenzoate 4-Methyl-2h-Chromen-2-On-7-Yl Sulphate And Use Thereof Patented View
18309948 Amino Pyrimidine Derivatives Abandoned View
17442650 Hpk1 Inhibitors Patented View
16613906 Exosome Production Promoter Abandoned View
16758368 Isoindoline Compositions And Methods For Treating Neurodegenerative Disease Abandoned View
17435819 Imidazopyridazine Compounds Useful As Modulators Of Il-12, Il-23 And/or Ifn Alpha Responses Patented View
17783336 6-Substituted, 22-Cyano Hyodeoxycholanic Analogues And Uses Thereof Abandoned View
17279107 Application Of Chiglitazar And Related Compounds Thereof Abandoned View
17431591 Novel Pyrido[3,4-D]pyrimidin-8-One Derivative Having Protein Kinase Inhibitory Activity, And Pharmaceutical Composition For Preventing, Alleviating, Or Treating Cancer, Comprising Same Abandoned View
18492627 Aminonaphthoquinone Compounds For Treatment And/or Prevention Of Fibrosis Diseases Patented View
18404967 Combination Treating Prostate Cancer, Pharmaceutical Composition And Treatment Method Abandoned View
16967130 Heterobicyclic Carboxylic Acids For Treating Cancer Or Inflammatory Diseases Abandoned View
17721067 Byl719 (Alpelisib) For Use In The Treatment Of Pik3ca-Related Overgrowth Spectrum (Pros-Cloves Syndrome) Patented View
17316643 Neostigmine Combination And Compositions Abandoned View
17845278 Use Of 1-[4-Bromo-5-[1-Ethyl-7-(Methylamino)-2-Oxo-1,2-Dihydro-1,6-Naphthyridin-3-Yl]-2-Fluorophenyl]-3-Phenylurea And Analogs For The Treatment Of Cancers Associated With Genetic Abnormalities In Platelet Derived Growth Factor Receptor Alpha Abandoned View
18101951 Polymorphs And Solid Forms Of (S)-2-((2-((S)-4-(Difluoromethyl)-2-Oxooxazolidin-3-Yl)-5,6-Dihydrobenzo[F]imidazo[1,2-D][1,4]oxazepin-9-Yl)amino)propanamide, And Methods Of Production Patented View
17239196 Inhibition Of Catalytic Site Common To Multiple 3 Alpha-Oxidoreductases For Treatment Of Prostate Cancer Abandoned View
16902189 Methods And Compositions For Modulating Th-Gm Cell Function Abandoned View
18484116 Proline-Based Neuropeptide Ff Receptor Modulators Patented View
18569434 Isoquinoline Alkaloid Compound, And Preparation Method Therefor And Use Thereof Abandoned View
18169734 Novel Cargo Delivery System And Composition Comprising The Same Patented View
16914862 Methods Of Use Of Cyclic Amide Derivatives To Treat Sigma Receptor Mediated Disorders Abandoned View
17331803 Liquid Laundry Product Comprising A Fragrance Composition Comprising Isopulegol Patented View
17041758 Pharmaceutical Compositions Comprising Timolol Abandoned View
18433196 Aryl Hydrocarbon Receptor Agonists And Uses Thereof Patented View
18046194 Identification Of Oleanolic Acid And Plant Extract For Glucose-6-Phosphate Dehydrogenase-Related Disorders Including Bag3opathy Patented View
17441355 Combinations Useful In A Method For Treating Sarcoma Abandoned View
18389456 Agonists Of Epha And Their Uses Abandoned View
17156233 Controlling Effects After 5ht2a Agonists Administration Abandoned View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.